Recent Quotes (30 days)

You have no recent quotes
chg | %

Miraculins Inc  

(Public, CVE:MOM)   Watch this stock  
Find more results for MOM
0.0000 (0.00%)
Aug 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.05 - 0.29
Open 0.05
Vol / Avg. 234,500.00/185,940.00
Mkt cap 2.63M
P/E     -
Div/yield     -
EPS -0.12
Shares 47.82M
Beta 0.23
Inst. own     -

Key stats and ratios

Q2 (May '15) 2015
Net profit margin -46247.02% -
Operating margin -38852.24% -
EBITD margin - -
Return on average assets -173.10% -
Return on average equity - -
CDP Score - -


6 - 1250 Waverley Street
+1-204-4531408 (Phone)
+1-204-4531546 (Fax)

Website links


Miraculins Inc. is a Canada-based development stage company focused on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs. The Company’s PreVu Non-Invasive Skin Cholesterol Test (PreVu) test is a non-invasive test which measures cholesterol in the skin tissues to assess risk of coronary artery disease (CAD) or heart disease. The PREVU Skin Cholesterol Test measures skin cholesterol. It also provides collaborators and customers with testing services using its PSP94 RUO kit. The Company has acquired a panel of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the program with Inverness Medical Innovations.

Officers and directors

Harry Bloomfield Independent Chairman of the Board
Christopher Moreau President, Chief Executive Officer, Director
James F. Kinley Chief Financial Officer
Age: 37
William Dwight Roberts Independent Director
Michael Stasiuk Independent Director